The little bottle: confessions of a nasal spray junkie

My name is beside the point; my profession probably is not: I have worked in a Swiss pharmacy for years. And I have a problem.

It fits in any handbag, any coat lining, any desk drawer. It costs less than ten francs. It is available without prescription. And I need it. At least three times a day. Sometimes more often.

I am talking about nasal spray. About that little plastic bottle with the thin nozzle that travels with me between lipstick and keyring on any private trip. I have them everywhere: in the car, in the office, in the bathroom, in the bedside table. One in the emergency supply in the kitchen – in case I need one “in an emergency”. And yes, I know how that sounds.

My pharmacy degree should have warned me. It did. We learned this, honestly. Rhinitis medicamentosa, privinism, rebound effect. Three different names, one diagnosis, and I knew them all long before I explained this diagnosis to patients. Today I still explain it – with the little plastic bottle in my apron pocket.

There are worse addictions. I tell myself that often. I do not drink too much, I take no illegal substances, I have neither a betting account nor an online shopping problem. My main vice fits into a 10-millilitre bottle and, statistically speaking, makes neither me nor anyone else immediately ill. That is the argument I put together for myself in the morning with the first spray. It works about as well as all arguments one puts together in the morning with the first spray.

“My pharmacy degree should have warned me. It did.”

What is actually happening in my nose?

Let us – before this gets too embarrassing – switch to pharmacology. What actually happens in a nose governed by a little plastic bottle?

The commercially available decongestant nasal sprays in Switzerland contain α-sympathomimetics of the imidazoline type: xylometazoline (Otrivin® and generics, ATC R01AA07), oxymetazoline (Nasivin®), naphazoline (known for decades under the brand name Privin® – hence the colloquial term “privinism”) and tramazoline. They bind with high affinity to α-adrenoceptors in the nasal mucosa, constrict the vessels, compress the swollen mucosa and open the nose. That happens within minutes and lasts, depending on the substance, three to twelve hours. A palpable pharmacological triumph: a gasping pause becomes breathing.

The problem begins when this triumph becomes a habit. With continuous use over more than five to seven days (some sources say after as few as three), a down-regulation of the α-receptors occurs, together with a negative feedback on endogenous noradrenaline production. The mucosa forgets how to regulate itself. When the exogenous vasoconstriction fades, the parasympathetic system dominates, the vessels widen, the mucosa swells more than before treatment. You spray again. You breathe briefly. It swells again. You spray again. Welcome to the rebound carousel.

This is – and as a pharmacist I find it particularly important to stress – not an addiction in the classic sense. There is no psychological dependence, no reward kick in the mesolimbic system, no dopamine surge. It is a physical development of tolerance with a pharmacologically enforced worsening of symptoms. It is not my brain that is addicted but my nasal mucosa. That makes it less romantic than other addictions, but unfortunately no less stubborn.

And yes, the consequences of chronic use are not merely cosmetic. Atrophy of the nasal mucosa, loss of the cilia, nosebleeds, crusting, in severe cases perforation of the nasal septum, disturbances of smell. The preservative benzalkonium chloride, contained in most sprays, reliably aids and abets – it is cytotoxic to the respiratory epithelium and aggravates the irritation. When I recommend a spray to patients today, I actively look for the preservative-free variants. I myself nonetheless often reach for the first bottle on the shelf. That too is part of the diagnosis.

How many of us are there?

How many of us are there, actually? Nobody knows exactly. There is no Swiss statistic on nasal spray dependence, which is not surprising: there is no diagnostic code for “patient is ashamed that he still needs Otrivin”. For Germany, health insurers estimate the number at 100,000 to one million affected. An ENT clinical incidence of 1 to 7 per cent is given. The Swiss extrapolation would be proportional, plus the usual unreported cases.

We are therefore not a small group. We are a large, very quiet group. Nobody writes song lyrics about us. Nobody makes documentaries. Even the rapper Sido admitted his dependence on Instagram only after 15 years of Otrivin use. He advised his fans to listen to the advice in the pharmacy. I find that touching every time.

Affected are above all middle-aged adults, women and men in equal measure. It usually begins with a real cold, an allergy, a sinusitis – that is, a situation in which the spray is clinically indicated. And then it drags on. One week becomes two. Two become six. And suddenly it is spring, the cold was in November, and the bottle is still standing on the bedside table.

“Nobody writes song lyrics about us.”

A little product study – the usual suspects

A little product study from the Swiss community pharmacy – essentially everything that can be dispensed without prescription and potentially becomes a privinism trap:

• Otrivin® (Haleon Schweiz AG, Risch) – xylometazoline 0.1 % or 0.05 % paediatric. Probably the best-known representative. Exists in countless variants: classic, plus (with ipratropium), cold set, menthol & eucalyptus, with/without preservative.
• Otrivin Cold Menthol deserves separate mention: the same active substance xylometazoline 0.1 %, but additionally with levomenthol and cineole (eucalyptus). This is the spray for the advanced user. Subjectively the most powerful effect – pharmacologically the potency is identical to the classic xylometazoline spray, but sensorily it feels like the first breath of mountain air after a 2,000-metre ascent. The reason: menthol docks onto the TRPM8 cold receptors of the nasal mucosa, producing an intense “freshness sensation” – and the brain interprets that as “clear airways” long before xylometazoline has any vasoconstrictive effect at all. That is precisely why it becomes the treatment of choice when the ordinary Otrivin “no longer really works” – which at some point happens to every chronic user. What is actually happening: the α-receptors are down-regulated, but the TRPM8-mediated subjective sensation can still be triggered for a while. Until it too no longer can. And then that is that. Pharmacologically no more harmless for it, but more irritating: the menthol intensifies the mucosal irritation, and the benzalkonium chloride it contains continues to lend a hand.
• Nasivin® (Procter & Gamble) – oxymetazoline. Acts somewhat longer, otherwise pharmacologically related.
• Triofan®, Rinosedin®, Nasenspray Spirig® – xylometazoline generics. Inexpensive, same mechanism, same trap.
• Vibrocil® (phenylephrine + dimetindene) – a combination of α-sympathomimetic and H1 antihistamine. Attractive where there is an allergic component; the rebound risk remains.
• Nasic® (xylometazoline + dexpanthenol) – with a wound-healing component, which theoretically spares the mucosa. Likes to market itself as the “friendlier” spray. Pharmacologically a sympathomimetic all the same.
• Rinofluimucil® (tuaminoheptane + N-acetylcysteine) – somewhat more exotic, same rebound logic, plus a mucolytic component.

What does not belong on this list, and this is important: isotonic or hypertonic saline solutions (Emser®, Rhinomer®, Otrimer®, Otrivin Natural Plus® eucalyptus), seawater sprays and glucocorticoid-containing nasal sprays (mometasone, fluticasone, beclometasone – in Switzerland formally List B, that is prescription-only; but they can be dispensed without prescription by the pharmacist via List B+ (consultation in the pharmacy) after documented counselling, provided the indication “allergic rhinitis” applies). These do not create dependence in the sense of rhinitis medicamentosa. They are the tools with which we get off the carousel.

How do you get out again?

There are three serious ways out of privinism, plus a pragmatic hybrid variant. I explain them to my patients daily. I use them on myself less often than I should. Do as I say, not as I do.

1. Cold turkey. You stop abruptly. You spend three to seven nights with bricked-up sinuses, longing glances at the empty bedside table and the realisation that you have never breathed so consciously. Then it is over. The α-receptors recover, the mucosa finds its autoregulation again, you breathe normally. Advantage: fast. Disadvantage: brutal. Works for people with pronounced willpower and/or the option of a week’s sick leave.
2. The one-nostril method. You continue to treat only one side of the nose and let the other go through cold withdrawal. You breathe through the “active” nostril while the “dry” one regenerates. After one to two weeks, when the abstinent side breathes normally again, you let the other side go too. Advantage: you can sleep at night. Disadvantage: during this phase you sometimes look a little… asymmetrically nasal. But that is a cosmetically very small problem.
3. The dilution method. You open the spray bottle, draw off part of the contents and top it up with physiological saline solution (NaCl 0.9 %). The concentration of the active substance falls step by step – today 0.1 %, tomorrow 0.08 %, next week 0.05 %, eventually 0 %. That makes it easier for the receptors to wind down. Advantage: very gentle. Disadvantage: laborious, and you need a syringe and some patience.
4. The pragmatic variant: switching to a glucocorticoid nasal spray. Mometasone, fluticasone or beclometasone – in Switzerland formally List B (prescription-only), but they can be dispensed without prescription by the pharmacist via List B+ (consultation in the pharmacy) after history-taking and documentation, where the indication is allergic rhinitis. They act anti-inflammatorily on the mucosa, not vasoconstrictively. They only really clear the nose after days to weeks, but without rebound. They can be used in parallel with the stepwise withdrawal of the sympathomimetic. In severe cases the ENT specialist even prescribes a short course of oral steroids (prednisone). Important to know: glucocorticoid sprays too frequently contain benzalkonium chloride, which can further irritate the already irritated mucosa. Preservative-free variants exist but are more expensive.

Always alongside: saline solutions. Hypertonic saline (Otrimeer® 2 %, Emser® Sole) osmotically draws water from the mucosa and has a mildly decongestant effect – without manipulating receptors. Drink plenty. Humidify the room air. If the nose does not clear after three to four weeks: ENT consultation. There are structural causes of chronic nasal obstruction – enlarged turbinates, polyps, septal deviation – that no nasal spray heals but only masks.

What the pharmacist can do

What can the pharmacist do? More than she usually does – and I do not exempt myself.

At first dispensing we should actively raise the maximum duration, not merely discreetly mention the package leaflet note. “A maximum of seven days. If after a week you still have a blocked nose, that is no longer a cold – that is something else, and we have to treat it differently.” This message takes twenty seconds. It works. Sometimes.

At repeat dispensing – and this is delicate – we should ask. Politely, without moralising. “How long have you been needing this now?” I know how that question sounds when you are on the other side of the counter and would have to answer honestly “for eleven years”. That is exactly why we should ask. Asking gives the other person permission to raise the subject.

Where privinism is suspected we should actively offer the withdrawal toolkit: hypertonic saline solution, a preservative-free glucocorticoid spray, perhaps a short written guide to the one-nostril method. It is counselling that costs time and appears in no tariff. It is nonetheless the most important service we can provide with this substance.

And we can – this matters to me particularly – tell patients that they are not alone. When I sell someone Otrivin for the fourth time in three months, I look at that person and say: “I know this may feel embarrassing. You are one of many thousands of Swiss people with this problem. We will get it under control.” Sometimes they smile awkwardly. Sometimes they cry a little. Sometimes the relief at not hearing the word “addiction” but “rebound mucosal reaction” is indescribably great.

Until then

So I have a problem. But if I am honest: I have it under control in so far as I know exactly what I am doing. I know the substances. I know the mechanism. I know the way out. I am just not taking it right now.

That is probably precisely the trap my patients fall into, and I do too. Knowledge does not protect you from the little plastic bottle in the handbag. Knowledge only protects you from lying to yourself about it.

Still: better than cocaine. Better than alcohol. Cheaper than online shopping. More socially acceptable than casino apps. Makes you neither fat nor stupid nor unemployed. Causes neither liver cirrhosis nor break-ups.

But at some point I will stop. Probably next week. Certainly next month. At the latest when this bottle is empty. And the one in the car. And the one in the office. And the one in the emergency supply in the kitchen.

Until then: if you stand across the counter from me with a little plastic bottle in your hand and an apologetic smile to go with it – I understand. We will get it under control. Both of us.